1) Temporal bone carcinoma is a rare and aggressive cancer, with squamous cell carcinoma being the most common type. It spreads along pathways in the temporal bone.
2) Surgery involves lateral, subtotal, or total temporal bone resection depending on tumor extent. More extensive resection provides wider margins but risks damage to nearby structures like cranial nerves.
3) Prognosis depends on tumor stage - early T1/T2 stages have close to 100% 2-year survival while advanced T4 has only 17% 2-year survival, as these tumors have often spread beyond the temporal bone.
Cavity obliteration is a procedure done at the end of Mastoidectomy to get a cavity-less mastoid cavity thus solving the problem of discharging post-operative cavity.
Cavity obliteration is a procedure done at the end of Mastoidectomy to get a cavity-less mastoid cavity thus solving the problem of discharging post-operative cavity.
Sinus tymapni shape and depth can influence surgical approach in cholesteatoma surgery. In the case of a shallower ST, an exclusive endoscopic exploration is chosen; while in the case of a deeper ST, a retrofacial approach is usually preferred.
Sinus tymapni shape and depth can influence surgical approach in cholesteatoma surgery. In the case of a shallower ST, an exclusive endoscopic exploration is chosen; while in the case of a deeper ST, a retrofacial approach is usually preferred.
Changes on Maxillary Sinus and Pharyngeal Airway Space after orthognathic sur...Turgut Novruzlu
Presentation about impact of Bimaxillary orthognathic surgery on Maxillary Sinuses and PAS. Evaluation with CBCT. Article investigation. 2018 Research, rejected null hypothesis that orthognathic surgeries does not affect dimensions maxillary sinuses and PAS. BSSO. Bilateral Split Sagittal Osteotomy, LeFort1
Naso-orbital-ethmoid (NOE) fractures: Management principles, options and rec...Dibya Falgoon Sarkar
Comprehensive discussion on diagnosis and management of NOE fractures. Surgical anatomy and approaches to NOE region is also discussed. Reconstruction of NOE complex is discussed. Recent advances in management of NOE fractures are also highlighted in this presentation
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
1. Surgery of the Temporal Bone
Carcinoma
1
M. Arif Sudianto Utama
2. Introduction
• Temporal bone carcinoma is a rare disease
• Very aggressive course
• If diagnosis is delayedBad prognosis
• Rapid progression and limited therapeutic success
• Squamous cell carcinoma (SCC) : Most common
primary (80%)
• 0.2% of all head and neck tumours
2
Ishak LN, Goh SB, Saim L, 2014; Beyea AJ, Moberly CA, 2015
3. Lecture Goals
3
Temporal bone anatomy
Malignant tumors
SCC and other primary tumors
Metastatic tumors
Surgical technic
4. Temporal Bone Anatomy : identifying pathways
of the spread of cancer
4
Axial Coronal
1
2
5
7
3
46
32
7
8
1
6
5
4
9
Hirsch EB, Chang JY, Antonio MS, 2009
5. 1. Anteriorly : cartilaginous ear canal parotid gland
2. Concha postauricular sulcus
3. Tympanic membrane middle ear
4. Posteriorly mastoid
5. Anterior mesotympanum carotid artery & eustachian tube
6. Inner ear round window or otic capsule
7. Along the facial nerve infratemporal fossa
8. Through the mastoid, posterior fossa dura, & sigmoid sinus
9. Beneath the skull base jugular fossa, carotid artery &
lower cranial nerves
5
Cancer can spread :
Hirsch EB, Chang JY, Antonio MS, 2009
10. Squamous cell carcinoma (SCC)
• Most common
• No sex prevalence
• Most patients have H/O chronic inflammation
of some kind
• S/S are otorrhea, HL and deep seated otalgia.
40% have a ME mass.
• Direct labyrinthine invasion is rare due to otic
capsule
10
Gustafson LM, Pensak LM, 2003; Noorizan Y, Asma A, 2010; Beyea AJ, Moberly CA, 2015
12. Squamous cell carcinoma
• Facial nerve involvement = advanced Dz
– CN VII paresis = 30-50% recurrence rate
– Paralysis = >60% recurrence
• Involvement of other CN = “dismal prognosis”
• CT and MRI are complimentary
• Consider angio with embo if surgery is feasible
12
Noorizan Y, Asma A, 2010; Beyea AJ, Moberly CA, 2015
13. Pittsburgh Staging System:
T classification
T1 : Tumor limited to the EAC; no bone erosion or soft tissue
extension
T2 : Tumor with limited bone erosion to the EAC or <0.5 cm of
soft tissue involvement
T3 : Tumor with full-thickness EAC bone erosion, <0.5-cm soft
tissue involvement, or tumor in the middle ear or mastoid
T4 : Tumor eroding the cochlea, petrous apex, medial wall of the
middle ear, carotid canal, jugular foramen, or dura; or >0.5-
cm soft tissue involvement; or facial nerve paresis
13
Hirsch EB, Chang JY, Antonio MS, 2009
14. N classification
• N0 : No regional nodes identified
• N1 : Single ipsilateral regional node <3 cm
• N2a : Single ipsilateral regional node 3–6 cm
• N2b : Multiple ipsilateral regional nodes 6 cm
• N2c : Bilateral or contralateral regional nodes
6 cm
• N3 : Regional node >6 cm
14
Hirsch EB, Chang JY, Antonio MS, 2009; Beyea AJ, Moberly CA, 2015
15. M classification
• M0 : Absence of distant metastatic disease
• M1 : Presence of distant metastatic disease
15
Overall stage
• I : T1N0M0
• II : T2N0M0
• III : T3N0M0
• IV : T4N0M0, T1–4N1M0, T1–4N0–3M1
Hirsch EB, Chang JY, Antonio MS, 2009; Beyea AJ, Moberly CA, 2015
19. Carotid Management
• T bone resection requires carotid control as
vessel passes thru medial to the Eustachian
tube before entering the cavernous sinus
• CT will show if the tumor is near the carotid
canal.
• 4 vessel angiography will show if vessel is
involved with tumor
19
Hirsch EB, Chang JY, Antonio MS, 2009; Marsh M, Jenkins A, 2010
20. Carotid BTO
• Balloon occlusion testing with Xenon/CT
– Investigate the collateral blood flow to ipsilateral
hemisphere
• 80% will tolerate ICA sacrifice
• 10% will not – necessitates prior bypass grafting (ECA to
MCA bypass) before T bone resection
• 10% grey zone – intraoperative or preoperative
revascularization
20
Hirsch EB, Chang JY, Antonio MS, 2009; Marsh M, Jenkins A, 2010
21. Lateral T Bone Resection
• En bloc removal of the entire EAC and TM
• Utilizes the extended facial recess approach
• May also include parotidectomy, ND and
mandibular condylectomy
• Involves resection of concha, may include
variable parts of the pinna and tragus PRN
21
Hirsch EB, Chang JY, Antonio MS, 2009; Marsh M, Jenkins A, 2010; Beyea AJ, Moberly CA, 2015
22. Lateral T Bone Resection
• Postauricular and
meatal incisions for
resection of the
temporal bone.
• This illustration
demonstrates inclusion
of the tragus with the
specimen
22
Hirsch EB, Chang JY, Antonio MS, 2009
23. Lateral T Bone Resection
23
•Closure of the EAC
•Complete mastoidectomy
•Extended facial recess
(sacrifice the chorda)
•Disarticulate the IS joint
•Fracture the anterior EAC
just lateral to the
Eustachian tube with
osteotome
•Watch out for ICA!
Hypotympanic
dissection
Specimen fractured
with osteotome
Specimen separated
from soft tissue
Marsh M, Jenkins A, 2010
24. • The anteriorly based
skin flap containing the
pinna is separated from
the core of the external
auditory meatus. The
meatus has been
oversewn to prevent
tumor spillage.
24
Hirsch EB, Chang JY, Antonio MS, 2009
25. Subtotal T Bone Resection
• Used with CA has penetrated into the ME space or
mastoid cavities
• Requires resection of the otic capsule
• Can be extended toward the ITF, jugular bulb or dura
as prescribed by tumor extent
• Should include monitoring of CN 7, 9, 10, 11
• If possible spare CN 7 by complete mobilization from
geniculate to foramen and transpose the nerve
posteriorly.
25
Hirsch EB, Chang JY, Antonio MS, 2009; Marsh M, Jenkins A, 2010; Beyea AJ, Moberly CA, 2015
26. Subtotal T Bone Resection
• The tegmen and posterior fossa plates are thinned
and then removed.
• A translab drill out of the IAC and jug bulb then done
– Allows further mobilization of the FN from the porus if
needed.
– The transected end of CN VIII should be sent for frozen
section
• Entire tympanic ring drilled out but leaving
periostium over ICA and lower CNs.
26
Hirsch EB, Chang JY, Antonio MS, 2009; Marsh M, Jenkins A, 2010; Beyea AJ, Moberly CA, 2015
27. C-shaped incision or Y-shaped incision
• Incisions include a central
external auditory canal core,
which is sutured closed
• Tragus can be preserved for
better cosmesis
• Temporal craniotomy for subtotal
temporal bone resection is
smaller than for a total temporal
bone resection
• Parotid gland with main trunk of
facial nerve has been elevated
from masseter muscle.
27
Marsh M, Jenkins A, 2010
28. Subtotal T Bone Resection
• Neck dissection
preformed for vascular
control of IJ and ICA
• Involvement of jugular
foramen necessitates IJ
sacrifice and ligation of
the sigmoid
– Avoid injury to vein of
Labbe – drainage of the
temporal lobe and can
result in venous
infarction of temporal
lobeBad!!
28
Marsh M, Jenkins A, 2010
29. Subtotal T Bone Resection
• Dural extension can be
resected with help of
neurosurgeon to close
the dural defect.
• Extension into the ITF
accomplished by
including a Fisch A ITF
approach
29
Marsh M, Jenkins A, 2010
31. Total T Bone Resection
• Used if tumor involves the petrous apex
• Mandates proximal and DISTAL control of the
ICA
– Distal control accomplished with middle cranial
fossa approach
• Requires division of CN 7, 8, 9, 10 and 11
– Done through a suboccipital crani
31
Hirsch EB, Chang JY, Antonio MS, 2009; Marsh M, Jenkins A, 2010; Beyea AJ, Moberly CA, 2015
32. • The ICA is completely mobilized or resected if
involved with tumor
• Osteotomy completed posterior to the foramen
ovale
32
Marsh M, Jenkins A, 2010
33. The temporal and
retrosigmoid portions of the
dura have been opened.
• N. VII through XI have been
transected
• The underlying dura incised as
the posterior border of the en
bloc resection of the petrous
bone
33
Marsh M, Jenkins A, 2010
36. Outcomes
• Tumors limited to the EAC have 50-80% cure rate
after LTBR
• Tumor extending beyond the ME 0-15% survival
>2yrs
• Survival increases with dual modality therapy
• University of Pittsburg staging system
– Increasing T stage is inversely proportional to survival
– T1 and T2 have reported 100% 2 yr survival
– T3 lesions have 2 yr of 56%
– 2 yr survival of T4 tumors at 17%
36
Hirsch EB, Chang JY, Antonio MS, 2009